The Maryland Prescription Drug Affordability Board voted on or before May 18, 2026, to cap Ozempic at $274 for a 30-day supply, effective January 2027, applied to state and local government employee health plans, according to reporting in STAT Pharmalot (Silverman, May 18, 2026). The board projects $5.8 million in annual savings, anchored verbatim to the Medicare Maximum Fair Price under the federal Inflation Reduction Act drug-price-negotiation program, per executive director Andrew York quoted by STAT.
Maryland is the first state to cap a GLP-1 receptor agonist by Upper Payment Limit. It is not, in its 2027 scope, the cap most Black Marylanders will encounter. The reasons sit in the gap between what Maryland's statute permits and what the May 2026 determination actually binds.
What the cap binds, and what it does not
The Maryland Prescription Drug Affordability Board has statutory authority under § 21-2C-14 of the Health-General Article to set upper payment limits on prescription drug products in three categories: drugs purchased by or for state and local government units, drugs paid through state and local government employee health benefit plans, and drugs purchased or paid for by the Maryland State Medical Assistance Program, which is the state's Medicaid program (Maryland General Assembly, Health-General § 21-2C-14). The board's January 2027 Ozempic determination, however, applies only to state and local government employee plans. STAT reported the board scoped the determination narrowly to avoid potential federal preemption questions around the Medicaid Drug Rebate Program, which governs Medicaid drug pricing through a separate statutory rebate floor and best-price calculation that operates outside state-set price ceilings (Silverman, STAT Pharmalot, May 18, 2026).
The $274 figure is anchored to the Medicare Maximum Fair Price for Ozempic. Ozempic appears on the second list of 15 drugs the Centers for Medicare and Medicaid Services selected for Medicare Drug Price Negotiation under the Inflation Reduction Act, with negotiated prices effective January 1, 2027 (CMS, IRA Negotiation Program). The Maryland board adopted the federal benchmark as its state-employee-plan ceiling. The board said in the same reporting that it expects to begin acting in 2028 to set upper payment limits on high-cost drugs purchased by all Marylanders in the commercial insurance market as well; the 2028 timeline is procedural, not committed regulatory calendar.
What the cap does not bind in 2027: Maryland Medicaid, Medicare Part B and D for Marylanders, commercial insurance for Marylanders not employed by state or local government, and the uninsured. The board-projected $5.8 million in annual savings accrues to state and local government employee plan budgets, not to enrollees in a direct subsidy.
Wasden 2026 documented a 49-percent prescribing gap that closed under uniform coverage
The peer-reviewed evidence base on US GLP-1 receptor agonist prescribing disparities reads as four overlapping claims, each anchored to a specific cohort.
A 2026 study of 2,060 patients at a Massachusetts tertiary-care weight-management clinic found that, before MassHealth expanded coverage of anti-obesity medications in April 2024, Black patients were 49 percent less likely to be prescribed semaglutide or tirzepatide than white patients (adjusted odds ratio, P = 0.003), and Hispanic patients were 47 percent less likely (P = 0.025) (Wasden et al., Obesity 2026, PMID 41771653). After MassHealth expansion, the racial and ethnic disparities diminished to non-significance. The mechanism, in the authors' framing, was insurance coverage terms; equalizing them collapsed the gap.
A 2026 study of 6,225 adults enrolled in Yale Health, a staff-model HMO with uniform coverage and uniform clinical access, found no significant disparity by race in GLP receipt for obesity treatment (adjusted OR 0.94, 95 percent confidence interval 0.78 to 1.13) (Chen et al., Journal of General Internal Medicine 2026, PMID 40588707). The null result is the counterweight that establishes the coverage mechanism. Black race did not predict prescription receipt when insurance terms and clinical access were equal.
A 2021 retrospective cohort of 1,180,260 patients with type 2 diabetes in OptumInsight Clinformatics Data Mart claims, October 2015 through June 2019, documented racial, ethnic, and socioeconomic inequities as the primary finding across a national commercially insured population (Eberly et al., JAMA Health Forum 2021, PMID 35977298). The cohort is the canonical pre-Wegovy-launch baseline; 90,934 patients in the sample, or 7.7 percent, received a GLP-1 receptor agonist during the study window.
Federal NHANES 2017-2018 data, the most recent NCHS Data Brief at the obesity-prevalence level, place non-Hispanic Black adult obesity prevalence at 49.6 percent and non-Hispanic Black women obesity prevalence at 56.9 percent. Both figures are significantly different from all other race and Hispanic-origin groups, with Black women carrying the highest prevalence of any race-sex group nationally (Hales et al., NCHS Data Brief No. 360, February 2020, PMID 32487284). The structural equation is highest documented baseline need, paired with the lowest documented prescription receipt in the studies of insurance-conditioned access.
The coverage-term mechanism that explains the Wasden disparity has a separate empirical anchor in Medicare Part D research. A 2012 quasi-experimental analysis of a 5-percent random sample of Medicare beneficiaries found that patients with no gap coverage had 60 percent higher adjusted odds of antihypertensive nonadherence during the Part D coverage gap, compared with Low-Income Subsidy-protected beneficiaries (Li, Doshi et al., Annals of Internal Medicine 2012, PMID 22665815). Lower copay raised adherence; higher cost barrier produced measurable cost-driven nonadherence. The mechanism is generic to prescription cost-sharing.
Where the cap reaches Black Marylanders, and where it does not
Maryland's Black residents are concentrated in Baltimore City, Prince George's County, parts of Montgomery and Charles counties, and the Eastern Shore. A large share of those residents are covered by the Maryland Medical Assistance Program, the state's Medicaid program. State and local government employee health plans, the only plans the May 2026 Upper Payment Limit binds, cover a much smaller slice of Maryland adults than Medicaid does.
The Wasden 2026 finding turned on a Medicaid coverage expansion. The Maryland board's 2027 action does not touch Medicaid. The Black-Marylander populations carrying the largest documented obesity and diabetes burden in the federal data sit in Medicaid, commercial insurance, and the uninsured population, not in state employee plans. The 2028 board-scheduled action on commercial-market UPLs is the next decision point at which the population the disparity literature names as least likely to receive GLP-1s could come inside a cap.
What you can do
If you are a Black Marylander covered under a Maryland state government, local government, or quasi-public employer health plan, ask the plan's benefits administrator how the January 2027 Upper Payment Limit on Ozempic will translate to formulary tier, prior authorization criteria, and the copay or coinsurance you pay at the pharmacy counter. The cap binds the net price the plan pays to the manufacturer. The pass-through to your out-of-pocket cost is a plan-design decision, not a board mandate.
If you are on Maryland Medicaid, on commercial insurance under a non-state-employer plan, or uninsured, your Ozempic price will not change in January 2027 under the May 2026 determination. The next decision point is the 2028 board-scheduled commercial-market action. The Maryland Prescription Drug Affordability Board posts board materials, dossiers, and meeting agendas at pdab.maryland.gov; the 2028 commercial-market regulatory action will move through public comment before it binds.
If you have been prescribed a GLP-1 receptor agonist or are considering one, the Wasden 2026 finding and the federal disparity baseline establish that coverage terms drive who gets the prescription, not the patient's race in isolation. Ask the prescribing provider whether your plan covers the drug for your indication, what the prior authorization requires, and whether any patient-assistance program reduces your out-of-pocket cost while coverage decisions sit in negotiation.
Citations
- Silverman E. "Maryland state affordability board places a price cap on Ozempic." STAT Pharmalot. May 18, 2026. https://www.statnews.com/pharmalot/2026/05/18/maryland-state-affordability-board-places-price-cap-on-ozempic/
- Maryland General Assembly. Health-General Article § 21-2C-14. https://mgaleg.maryland.gov/mgawebsite/Laws/StatuteText?article=ghg§ion=21-2C-14
- Centers for Medicare and Medicaid Services. Medicare Drug Price Negotiation Program. https://www.cms.gov/inflation-reduction-act-and-medicare/medicare-drug-price-negotiation
- Wasden K, Sheu N, Medhati P, et al. "Disparities in Prescription of Long-Acting GLP-1s." Obesity (Silver Spring) 2026. PMID 41771653. https://pubmed.ncbi.nlm.nih.gov/41771653/
- Chen AS, Brunetto W, Canavan ME, et al. "Prescribing GLPs for Obesity Treatment for Adults at a University Based Health Maintenance Organization by Race, Ethnicity, and Socioeconomic Status." Journal of General Internal Medicine 2026. PMID 40588707. https://pubmed.ncbi.nlm.nih.gov/40588707/
- Eberly LA, Yang L, Essien UR, et al. "Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US." JAMA Health Forum 2021;2(12):e214182. PMID 35977298. https://pubmed.ncbi.nlm.nih.gov/35977298/
- Hales CM, Carroll MD, Fryar CD, Ogden CL. "Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018." NCHS Data Brief No. 360, February 2020. PMID 32487284. https://www.cdc.gov/nchs/data/databriefs/db360-h.pdf
- Li P, McElligott S, Bergquist H, Schwartz JS, Doshi JA. "Effect of the Medicare Part D coverage gap on medication use among patients with hypertension and hyperlipidemia." Annals of Internal Medicine 2012;156(11):776-784. PMID 22665815. https://pubmed.ncbi.nlm.nih.gov/22665815/
- Maryland Prescription Drug Affordability Board. Board Selected Drugs and any applicable information. https://pdab.maryland.gov/Pages/board-selected-da-info.aspx
